Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice.
Abstract Cytoreductive nephrectomy (CN) followed by systemic therapy had been considered the standard of care for metastatic renal cell carcinoma (mRCC) patients since two clinical trials established its role during the cytokines era. With introduction of new and effective drugs, such as vascular endothelial growth factor-targeted therapies, the role of CN started to be challenged. Retrospective studies conducted during the targeted therapy era pointed to better outcomes when CN was associated with systemic treatment, although certain patients with poor risk features did not seem to benefit. Therefore, prospective...
Source: Oncology - September 12, 2019 Category: Cancer & Oncology Authors: Soares A, Maia MC, Vidigal F, Marques Monteiro FS Tags: Oncology Source Type: research

Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma.
CONCLUSIONS: Imatinib showed no measurable activity in patients with newly diagnosed or recurrent glioblastoma. PMID: 31514200 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - September 12, 2019 Category: Cancer & Oncology Authors: Sautter L, Hofheinz R, Tuettenberg J, Grimm M, Vajkoczy P, Groden C, Schmieder K, Hochhaus A, Wenz F, Giordano FA Tags: Oncology Source Type: research

Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer.
This study included 41 advanced gastric cancer patients who were treated with NAC followed by surgery. Body composition was assessed before and after NAC. The relationship between the pre-NAC body composition and adverse events was investigated as well as the relationship between changes in body composition and adverse events. RESULTS: Univariate and multivariate analyses revealed that low pre-NAC skeletal muscle mass was the only factor significantly associated with severe diarrhea (p = 0.03). There was no significant difference in body weight before and after NAC, but skeletal muscle mass was significantly reduced a...
Source: Oncology - September 11, 2019 Category: Cancer & Oncology Authors: Matsuura N, Motoori M, Fujitani K, Nishizawa Y, Komatsu H, Miyazaki Y, Miyazaki S, Tomokuni A, Komori T, Iwase K Tags: Oncology Source Type: research

Histologic Response and Toxicity following Interval-Compressed Four-Drug Therapy Given Preoperatively in Children and Young Adults with Osteosarcoma: A Retrospective Study.
CONCLUSIONS: Interval-compressed MAPI therapy given in a similar duration of the preoperative phase to that of conventional MAP therapy showed a marginal trend toward a better histologic response without a significant increase in major toxicities. Regarding the proportion of good histologic response, 71% is one of the highest values ever reported in the literature. The results warrant further testing in a prospective way in a larger cohort. PMID: 31509843 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - September 11, 2019 Category: Cancer & Oncology Authors: Kang JM, Ju HY, Joo J, Sung JY, Park SY, Kim JH, Kang HG, Kwon M, Park M, Park HJ, Park BK Tags: Oncology Source Type: research

Metachronous and Synchronous Cancers in Patients with Neuroendocrine Tumors.
CONCLUSIONS: Only few studies have examined the association between NETs and SPMs. Our study showed that the risk of second cancer following NETs is increased. In this single-institution retrospective review, our incidence of additional malignancies in patients with NET was 11.4%. PMID: 31505502 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - September 10, 2019 Category: Cancer & Oncology Authors: Verrico M, Rossi L, Tomao S, Colonna M, Vici P, Tomao F Tags: Oncology Source Type: research

Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
CONCLUSIONS: Non-small cell lung carcinoma patients in whom an EGFR T790M mutation was detected in plasma samples demonstrated a poorer response to osimertinib than those in whom the mutation was detected in tissue specimens. PMID: 31494653 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - September 6, 2019 Category: Cancer & Oncology Authors: Ikushima H, Sakatani T, Usui K Tags: Oncology Source Type: research

Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
CONCLUSION: The present study determined the dose for further clinical trials of IP PTX to be 20 mg/m2, when combined with the 5-weekly SP regimen. PMID: 31487733 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - September 5, 2019 Category: Cancer & Oncology Authors: Kobayashi D, Ishigami H, Kanda M, Tanaka C, Yamaguchi H, Kitayama J, Kodera Y Tags: Oncology Source Type: research

Efficacy of Vinorelbine Monotherapy as Third- or Further-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer.
CONCLUSIONS: Weekly vinorelbine monotherapy may be a feasible therapeutic option for patients with heavily treated, advanced NSCLC, particularly lung adenocarcinoma. PMID: 31480050 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - September 3, 2019 Category: Cancer & Oncology Authors: Kang DH, Kim JO, Jung SS, Park HS, Chung C, Park D, Lee JE Tags: Oncology Source Type: research

Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
ka K, On behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Abstract BACKGROUND/AIM: Lenvatinib (LEN) has been developed for the treatment of unresectable hepatocellular carcinoma (u-HCC). We aimed to elucidate the relative change in hepatic reserve function early following LEN treatment in affected patients. MATERIALS/METHODS: From March 2018 to April 2019, 123 u-HCC patients (median age 71 years; male:fem...
Source: Oncology - August 29, 2019 Category: Cancer & Oncology Authors: Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michit Tags: Oncology Source Type: research

Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Abstract BACKGROUND: Preoperative therapy followed by surgery has become the clinical standard for resectable advanced esophageal cancer. Several studies showed that neoadjuvant docetaxel/cisplatin/5-fluorouracil (DCF) resulted in a high response rate and prolonged relapse-free survival, but what constitutes appropriate additional therapy is unknown. METHODS: A total of 101 consecutive patients with cStage I B-III esophageal cancer were treated with preoperative DCF between April 2011 and December 2015. After completing 2 cycles of DCF neoadjuvant chemotherapy (NAC), esophagectomy was performed. We investigat...
Source: Oncology - August 28, 2019 Category: Cancer & Oncology Authors: Sugimura K, Miyata H, Shinno N, Ushigome H, Asukai K, Yanagimoto Y, Hasegawa S, Takahashi Y, Yamada D, Yamamoto K, Nishimura J, Motoori M, Wada H, Takahashi H, Yasui M, Omori T, Ohue M, Yano M Tags: Oncology Source Type: research

Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen.
DISCUSSION: In this real-word non-randomized clinical trial setting, the data showed that vinflunine is an efficacious and safe therapeutic option for second-line treatment of patients with metastatic urothelial carcinoma of the bladder after a platinum-containing regimen. PMID: 31461721 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - August 28, 2019 Category: Cancer & Oncology Authors: De Luca R, Profita G, Vella M, Cicero G Tags: Oncology Source Type: research

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
CONCLUSION: The current meta-analysis showed a high sensitivity and specificity of 18F-FDG-PET or PET/CT for the detection of recurrent disease after treatment of MM. The LR scattergram indicated that 18F-FDG-PET or PET/CT is useful for exclusion and confirmation of recurrent disease after treatment of MM. PMID: 31437839 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - August 22, 2019 Category: Cancer & Oncology Authors: Lee JW, Nam SB, Kim SJ Tags: Oncology Source Type: research

The EOLO (End-of-Life Ovarian Cancer) Study: Approach to Ovarian Cancer Patients at the End of Life.
CONCLUSIONS: End-of-life chemotherapy for OC patients is a thorny problem. More studies and a multidisciplinary approach are needed to better treat these patients. PMID: 31437848 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - August 22, 2019 Category: Cancer & Oncology Authors: Palaia I, Tomao F, Santangelo G, Di Pinto A, Sassu CM, Perniola G, Musella A, Di Donato V, Giancotti A, Benedetti Panici P Tags: Oncology Source Type: research

Impact of Cigarette Smoking and Head and Neck Squamous Cell Carcinoma on Circulating Inflammatory Biomarkers.
CONCLUSION: IdentifyingHNSCC or smoking-related inflammatory biomarkers might contribute to the understanding of the immune response in HNSCC patients. This study could provide information of inflammatory biomarkers in HNSCC patients. PMID: 31437849 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - August 22, 2019 Category: Cancer & Oncology Authors: Andersson BÅ, Löfgren S, Lewin F, Nilsson M, Laytragoon-Lewin N Tags: Oncology Source Type: research

Epidermal Growth Factor Potentiates Migration of MDA-MB 231 Breast Cancer Cells by Increasing NaV1.5 Channel Expression.
In this study, by using an experimental strategy that combines cell and molecular biology assays with electrophysiological recording, we sought to determine whether the voltage-dependent sodium channel NaV1.5 regulates the migratory capacity of the human breast cancer cell line MDA-MB 231, when cells are maintained in the presence of epidermal growth factor (EGF), as an inductor of the epithelial-mesenchymal transition. RESULTS: Our data show that EGF stimulates the migratory capacity of MDA-MB 231 cells, by regulating the functional expression of NaV1.5 channels. Consistent with this, the stimulatory actions of the g...
Source: Oncology - August 20, 2019 Category: Cancer & Oncology Authors: González-González L, González-Ramírez R, Flores A, Avelino-Cruz JE, Felix R, Monjaraz E Tags: Oncology Source Type: research

Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
CONCLUSION: Concerning the urgency of early and frequent detection, staging, and disease monitoring of mammary carcinoma with osseous metastases, this study renewed and underlined the importance of biochemical tumor markers - especially β-CTx and B-AP - and laid a clinical-based cornerstone to build up on a prospective research. PMID: 31412345 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - August 14, 2019 Category: Cancer & Oncology Authors: Zulauf N, Brüggmann D, Groneberg D, Oremek GM Tags: Oncology Source Type: research

A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.
CONCLUSIONS: While this trial did not meet the primary endpoint, the sufficient efficacy and feasibility of gemcitabine maintenance therapy were suggested. PMID: 31412347 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - August 14, 2019 Category: Cancer & Oncology Authors: Ikeda S, Yoshioka H, Kaneda T, Yokoyama T, Niwa T, Sone N, Ishida T, Morita M, Tomioka H, Komaki C, Hirabayashi M, Hasegawa Y, Noguchi T, Nakano Y, Sakaguchi C, Yoshimura K, Hirai T Tags: Oncology Source Type: research

Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature.
Abstract Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma in combination with everolimus. LEN-treated patients frequently have adverse events (AEs) that generally require such dose modifications, including drug discontinuation. Hypertension, diarrhea, weight loss, proteinuria, fatigue, and palmar-plantar erythrodysesthesia are reported among the most frequent AEs, often leading to discontinuations or dose modifications. This paper reports a case series focus...
Source: Oncology - August 7, 2019 Category: Cancer & Oncology Authors: Denaro N, Latina A, Cesario F, Bramardi F, Corrado L, Borretta G, Merlano MC Tags: Oncology Source Type: research

Recognition and Treatment of Adrenal Insufficiency Secondary to Abiraterone: A Case Report and Literature Review.
CONCLUSIONS: We found that a standard dose of prednisone of 5 mg/day as recommended previously may be inadequate to achieve physiologic glucocorticoid replacement in some patients with prostate cancer while on abiraterone treatment and as a result adrenal insufficiency due to inadequate dosing might be more common than initially thought. Additionally 10 mg of prednisone daily may cause adverse effects in some patients. Thus clinicians should be aware of the potential for development of adrenal insufficiency or symptoms of glucocorticoid excess in these patients receiving prednisone so that appropriate modifications in...
Source: Oncology - August 7, 2019 Category: Cancer & Oncology Authors: Baloch HM, Grice-Patil ZJ, Selig DJ, Hoang TD, Mai VQ, Shakir MK Tags: Oncology Source Type: research

Distribution of Neuroendocrine Marker-Positive Cells in Colorectal Cancer Tissue and Normal Mucosal Tissue: Consideration of Histogenesis of Neuroendocrine Cancer.
CONCLUSIONS: Neuroendocrine marker-positive cells in colorectal cancer tissue are more common in the right sided colon, whereas neuroendocrine marker-positive cells in normal mucosa are more common in the rectum. These results suggest that NEC may arise from preceding adenocarcinomas. PMID: 31390635 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - August 7, 2019 Category: Cancer & Oncology Authors: Ogimi T, Sadahiro S, Kamei Y, Chan LF, Miyakita H, Saito G, Okada K, Suzuki T, Kajiwara H Tags: Oncology Source Type: research

Lenvatinib Real-Life Experience.
PMID: 31390640 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - August 7, 2019 Category: Cancer & Oncology Authors: Markman M Tags: Oncology Source Type: research

Feasibility and Usability Aspects of Continuous Remote Monitoring of Health Status in Palliative Cancer Patients Using Wearables.
r M Abstract BACKGROUND: Mobile health is a promising strategy aiming to anticipate and prevent the deterioration of health status in palliative cancer patients. A prerequisite for successful implementation of this technology into clinical routine is a high level of usability and acceptance of devices. OBJECTIVES: We aimed to evaluate feasibility as well as patients' acceptance of remote monitoring using wearables in palliative cancer patients. METHODS: In this prospective single-center observational feasibility study, 30 cancer patients treated with palliative intent in an inpatient setting with an esti...
Source: Oncology - July 23, 2019 Category: Cancer & Oncology Authors: Pavic M, Klaas V, Theile G, Kraft J, Tröster G, Guckenberger M Tags: Oncology Source Type: research

Overcoming Tamoxifen Resistance by Regulation of Del-1 in Breast Cancer.
CONCLUSIONS: TAM-R breast cancer is characterized by Del-1 overexpression and tumor progression can be inhibited by Del-1 depletion, which restores TAM sensitivity. Thus, therapeutic strategies that target Del-1 may be effective for the treatment of hormone-resistant breast cancer. PMID: 31330520 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - July 22, 2019 Category: Cancer & Oncology Authors: Lee J, Jeong JH, Jung JH, Kim WW, Lee SJ, Park JY, Park JY, Kang SH, Kim EA, Park JH, Chae YS, Park HY Tags: Oncology Source Type: research

Radiographic Assessment of Objective Responses Using the ITMIG-Modified Criteria in Thymic Carcinoma.
CONCLUSION: The ITMIG-modified criteria showed a high concordance rate with RECIST 1.1 criteria in response assessment of thymic carcinoma. PMID: 31307031 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - July 15, 2019 Category: Cancer & Oncology Authors: Hakozaki T, Okuma Y, Hosomi Y, Hishima T Tags: Oncology Source Type: research

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
CONCLUSION: Good hepatic function (mALBI 1/2a) at introduction of the initial TKI is a requirement for improved prognosis of u-HCC undergoing TKI sequential therapy. PMID: 31307035 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - July 15, 2019 Category: Cancer & Oncology Authors: Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Tags: Oncology Source Type: research

The Evolving Arena of Ovarian Cancer Maintenance Therapy.
Abstract Based on the results of several phase 3 randomized trials, "maintenance therapy" (prolonged treatment after an initial response to cytotoxic chemotherapy) has assumed a critical role in the routine care of advanced epithelial ovarian cancer. While earlier data had provided support for this therapeutic concept in disease management (e.g., multiple cycles of single-agent paclitaxel following a clinical complete response to a platinum/paclitaxel regimen), more recent data has revealed both the efficacy and safety of the anti-angiogenesis agent, bevacizumab, and several PARP inhibitors when employed...
Source: Oncology - July 9, 2019 Category: Cancer & Oncology Authors: Markman M Tags: Oncology Source Type: research

The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
CONCLUSIONS: In our cohort of GBM patients treated with combined modality therapy, pretreatment NLR was not prognostic. Toxicity of treatment was acceptable. Investigation of the NLR with larger groups of patients selected by MGMT status is warranted. PMID: 31288238 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - July 9, 2019 Category: Cancer & Oncology Authors: Brenner A, Friger M, Geffen DB, Kaisman-Elbaz T, Lavrenkov K Tags: Oncology Source Type: research

Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials
Conclusions: RFSF related to organ function rarely deteriorate unless directly involved with underlying malignancy. Most RFSF do not prevent patients from having SST, nor increase dose reductions, especially in treatment-na ïve/phase III trial-ineligible patients. Those with RFSF of poor PS, rapid PD, and aLFT from LM are less suitable for SST. Careful broadening of trial eligibility is warranted.Oncology (Source: Oncology)
Source: Oncology - July 2, 2019 Category: Cancer & Oncology Source Type: research

A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer
Conclusions: XELOXIRI is a feasible and active regimen for patients with locally advanced rectal cancer. Febrile neutropenia was the DLT, and the RD of irinotecan is 150 mg/m2.Oncology (Source: Oncology)
Source: Oncology - July 2, 2019 Category: Cancer & Oncology Source Type: research

Special Focus on Stage IV Cervical Cancer Patients: A Decade Experience
Conclusions: In daily clinical practice, outcomes of stages IV CC are poor. Treatment of advanced and metastatic CC remains challenging. New management strategies are needed, as well as efficient preventive strategies.Oncology (Source: Oncology)
Source: Oncology - July 2, 2019 Category: Cancer & Oncology Source Type: research

Local Therapy in Advanced Cholangiocarcinoma: A Review of Current Endoscopic, Medical, and Oncologic Treatment Options
Endoscopic decompression of bile duct stenosis in unresectable cholangiocarcinoma (CC) may be difficult due to localization of the tumor, but it is important for pursuing oncologic treatment afterwards. Besides the initial diagnosis, jaundice and cholangitis are the most important indications for immediate endoscopic treatment. Endoscopic retrograde cholangiopancreatography is the favored approach for biliary access and stent placement. Hilar tumors are more difficult to treat and sometimes need higher endoscopic or radiologic expertise. In general, biliary decompression is accompanied by antibiotic treatment. Oncologic tr...
Source: Oncology - July 2, 2019 Category: Cancer & Oncology Source Type: research

Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials.
CONCLUSIONS: RFSF related to organ function rarely deteriorate unless directly involved with underlying malignancy. Most RFSF do not prevent patients from having SST, nor increase dose reductions, especially in treatment-naïve/phase III trial-ineligible patients. Those with RFSF of poor PS, rapid PD, and aLFT from LM are less suitable for SST. Careful broadening of trial eligibility is warranted. PMID: 31266008 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - July 2, 2019 Category: Cancer & Oncology Authors: Tiu C, Loh Z, Gan CL, Gan H, John T, Hawkes E Tags: Oncology Source Type: research

A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer.
CONCLUSIONS: XELOXIRI is a feasible and active regimen for patients with locally advanced rectal cancer. Febrile neutropenia was the DLT, and the RD of irinotecan is 150 mg/m2. PMID: 31266024 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - July 2, 2019 Category: Cancer & Oncology Authors: Kudo T, Takemasa I, Hata T, Sakai D, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Satoh T, Mizushima T, Mori M, Doki Y Tags: Oncology Source Type: research

Special Focus on Stage IV Cervical Cancer Patients: A Decade Experience.
CONCLUSIONS: In daily clinical practice, outcomes of stages IV CC are poor. Treatment of advanced and metastatic CC remains challenging. New management strategies are needed, as well as efficient preventive strategies. PMID: 31266037 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - July 2, 2019 Category: Cancer & Oncology Authors: Espenel S, Garcia MA, Langrand-Escure J, Vallard A, Trone JC, Rancoule C, Vial N, Moreno-Acosta P, Chauleur C, Boutet C, Peoc Apos H M, Prevot-Bitot N, Guy JB, Magné N Tags: Oncology Source Type: research

Local Therapy in Advanced Cholangiocarcinoma: A Review of Current Endoscopic, Medical, and Oncologic Treatment Options.
iat R Abstract Endoscopic decompression of bile duct stenosis in unresectable cholangiocarcinoma (CC) may be difficult due to localization of the tumor, but it is important for pursuing oncologic treatment afterwards. Besides the initial diagnosis, jaundice and cholangitis are the most important indications for immediate endoscopic treatment. Endoscopic retrograde cholangiopancreatography is the favored approach for biliary access and stent placement. Hilar tumors are more difficult to treat and sometimes need higher endoscopic or radiologic expertise. In general, biliary decompression is accompanied by antibiotic...
Source: Oncology - July 2, 2019 Category: Cancer & Oncology Authors: Jung CFM, Lavole J, Barret M, Abou Ali E, Palmieri LJ, Dermine S, Barré A, Chaussade S, Coriat R Tags: Oncology Source Type: research

Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience
Chimeric antigen receptor (CAR) modified T-cell therapy, a unique platform technology highlighting precision medicine through utilization of molecular biology and cell-based therapeutics has shown unprecedented rates in patients with hematological malignancies such as acute lymphocyte leukemia, non-Hodgkin ’s lymphoma and multiple myeloma (MM). With the approval of CD19-targeted CAR T-cells by the Food and Drug Administration in acute lymphoblastic leukemia (ALL) and NHL, this technology is positioned for aggressive expansion to combination therapeutic opportunities and proof of principle towards ut ility in other ma...
Source: Oncology - July 1, 2019 Category: Cancer & Oncology Source Type: research

Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.
Abstract Chimeric antigen receptor (CAR) modified T-cell therapy, a unique platform technology highlighting precision medicine through utilization of molecular biology and cell-based therapeutics has shown unprecedented rates in patients with hematological malignancies such as acute lymphocyte leukemia, non-Hodgkin's lymphoma and multiple myeloma (MM). With the approval of CD19-targeted CAR T-cells by the Food and Drug Administration in acute lymphoblastic leukemia (ALL) and NHL, this technology is positioned for aggressive expansion to combination therapeutic opportunities and proof of principle towards utility i...
Source: Oncology - July 1, 2019 Category: Cancer & Oncology Authors: Metzinger MN, Verghese C, Hamouda DM, Lenhard A, Choucair K, Senzer N, Brunicardi FC, Dworkin L, Nemunaitis J Tags: Oncology Source Type: research

Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib
Conclusion: With lenvatinib therapy for HCC, the AFP levels of most patients had declined at 2 weeks, and at 4 weeks the AFP-sustained-reduction group demonstrated a higher objective response.Oncology (Source: Oncology)
Source: Oncology - June 26, 2019 Category: Cancer & Oncology Source Type: research

Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
CONCLUSION: With lenvatinib therapy for HCC, the AFP levels of most patients had declined at 2 weeks, and at 4 weeks the AFP-sustained-reduction group demonstrated a higher objective response. PMID: 31242488 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - June 26, 2019 Category: Cancer & Oncology Authors: Kodama K, Kawaoka T, Namba M, Uchikawa S, Ohya K, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Imamura M, Chayama K, Aikata H Tags: Oncology Source Type: research

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
Conclusions: The combination of ibrutinib 560 mg daily and durvalumab 10 mg/kg every 2 weeks had an acceptable safety profile. The antitumor activity of the ibrutinib-durvalumab combination was limited in our study population.Oncology (Source: Oncology)
Source: Oncology - June 21, 2019 Category: Cancer & Oncology Source Type: research

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
CONCLUSIONS: The combination of ibrutinib 560 mg daily and durvalumab 10 mg/kg every 2 weeks had an acceptable safety profile. The antitumor activity of the ibrutinib-durvalumab combination was limited in our study population. PMID: 31230047 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - June 21, 2019 Category: Cancer & Oncology Authors: Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E Tags: Oncology Source Type: research

Drug Management in End-of-Life Hospitalized Palliative Care Cancer Patients: The RHESO Cohort Study
Conclusions: NACT prescription remained commonplace in terminally ill palliative cancer patients, although their benefit is questionable.Oncology (Source: Oncology)
Source: Oncology - June 20, 2019 Category: Cancer & Oncology Source Type: research

Drug Management in End-of-Life Hospitalized Palliative Care Cancer Patients: The RHESO Cohort Study.
CONCLUSIONS: NACT prescription remained commonplace in terminally ill palliative cancer patients, although their benefit is questionable. PMID: 31220846 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - June 20, 2019 Category: Cancer & Oncology Authors: Vallard A, Morisson S, Tinquaut F, Chauvin F, Oriol M, Chapelle C, Sotton S, Magné N, Tardy B, Bourmaud A Tags: Oncology Source Type: research

Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice
Conclusions: IO patients showed significant benefit in OS with HRs comparable to those reported in phase III trials. The benefit tended to be greater in patients with lower tumor mass.Oncology (Source: Oncology)
Source: Oncology - June 19, 2019 Category: Cancer & Oncology Source Type: research

Stool-Based miR-92a and miR-144* as Noninvasive Biomarkers for Colorectal Cancer Screening
Conclusions: The stool levels of miR-92a and miR-144* showed good sensitivity and fair specificity for detection of CRC, and thus may be useful as noninvasive biomarkers for this disease.Oncology (Source: Oncology)
Source: Oncology - June 19, 2019 Category: Cancer & Oncology Source Type: research

Rac GTPase-Activating Protein 1 (RACGAP1) as an Oncogenic Enhancer in Esophageal Carcinoma
Conclusions: RACGAP1 plays a pivotal role in EC development, suggesting that it could be used as an indicator of prognosis in EC patients.Oncology (Source: Oncology)
Source: Oncology - June 19, 2019 Category: Cancer & Oncology Source Type: research

Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1
Conclusions: Prolonged low levels of a granulocyte-related systemic inflammatory response after the early period of therapy and low cytoplasmic WT1 expression in PDA cells may be markers predictive of OS in PDA patients receiving WT1-targeting immunochemotherapy.Oncology (Source: Oncology)
Source: Oncology - June 19, 2019 Category: Cancer & Oncology Source Type: research

Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
Abstract BACKGROUND: We have developed a Wilms' tumor 1 (WT1)-targeting dendritic cell (DC)-based cancer vaccine combined with standard chemotherapy for patients with advanced pancreatic ductal adenocarcinoma (PDA). METHODS: We evaluated predictive markers of overall survival (OS) in PDA patients treated with multiple major histocompatibility complex class I/II-restricted, WT1 peptide-pulsed DC vaccinations (DC/WT1-I/II) in combination with chemotherapy. Throughout the entire period of immunochemotherapy, the plasma levels of soluble factors derived from granulocytes of 7 eligible PDA patients were examined. ...
Source: Oncology - June 19, 2019 Category: Cancer & Oncology Authors: Ito Z, Kan S, Bito T, Horiuchi S, Akasu T, Yoshida S, Kajihara M, Hokari A, Saruta M, Yoshida N, Kobayashi M, Ohkusa T, Shimodaira S, Okamoto M, Sugiyama H, Koido S Tags: Oncology Source Type: research

Rac GTPase-Activating Protein 1 (RACGAP1) as an Oncogenic Enhancer in Esophageal Carcinoma.
This study investigated the clinical importance and functional role of RACGAP1 in esophageal carcinoma (EC). METHODS: A total of 81 EC patients were enrolled in the study. We assessed the immunohistochemical score of EC tissues and adjacent normal esophageal mucosae, and then performed multiple cell function tests by means of in vitro experiments to elucidate the functional role of RACGAP1 using RNA interference technology in EC cell lines. RESULTS: RACGAP1 was significantly overexpressed in EC tissues compared with the adjacent normal esophageal mucosae (p
Source: Oncology - June 19, 2019 Category: Cancer & Oncology Authors: Yin C, Toiyama Y, Okugawa Y, Shigemori T, Yamamoto A, Ide S, Kitajima T, Fujikawa H, Yasuda H, Okita Y, Hiro J, Yoshiyama S, Ohi M, Araki T, Yao L, Kusunoki M Tags: Oncology Source Type: research

Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.
CONCLUSIONS: IO patients showed significant benefit in OS with HRs comparable to those reported in phase III trials. The benefit tended to be greater in patients with lower tumor mass. PMID: 31216560 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - June 19, 2019 Category: Cancer & Oncology Authors: Faehling M, Kopp M, Schwenk B, Fallscheer S, Kramberg S, Eckert R Tags: Oncology Source Type: research